| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/09/2011 | WO2011108963A1 Urethanes, ureas, amidines and related inhibitors of factor xa |
| 09/09/2011 | WO2011108961A1 Pyridopyrazindione derivative and use thereof as an antiulcer agent |
| 09/09/2011 | WO2011108946A1 Methods for improving sperm functionality |
| 09/09/2011 | WO2011108930A1 A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
| 09/09/2011 | WO2011108762A1 Prophylactic and/or ameliorating agent for insulin resistance |
| 09/09/2011 | WO2011108724A1 Prophylactic or therapeutic agent for diabetes or obesity |
| 09/09/2011 | WO2011108690A1 Alkylamine derivative |
| 09/09/2011 | WO2011108689A1 Pyrazolopyrimidine derivative |
| 09/09/2011 | WO2011108686A1 Substance derived from grifola frondosa for inhibiting increase of postprandial hyperglycemia |
| 09/09/2011 | WO2011108644A1 Solid pharmaceutical composition and pharmaceutical preparation |
| 09/09/2011 | WO2011108643A1 Film preparation containing medicament with unpleasant taste |
| 09/09/2011 | WO2011108499A1 Osteoblast differentiation promoter, pharmaceutical composition for promoting ossification, and health food containing auraptene analog as active ingredient |
| 09/09/2011 | WO2011108487A1 Muscular atrophy inhibitor |
| 09/09/2011 | WO2011108471A1 Virus inhibitor |
| 09/09/2011 | WO2011108009A2 Process for the preparation of fampridine |
| 09/09/2011 | WO2011108006A2 A novel liquid oral spray dosage form comprising thiocolchicoside and anti-inflammatory agent |
| 09/09/2011 | WO2011108000A1 Isolation of a natural lead with potential of p38 mitogen activated protein kinase and c-jun-n terminal kinase inhibiting activity |
| 09/09/2011 | WO2011107981A1 A3ar agonists for the treatment of uveitis |
| 09/09/2011 | WO2011107970A2 Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect. |
| 09/09/2011 | WO2011107948A2 Ligands of insulin degrading enzyme and their uses |
| 09/09/2011 | WO2011107912A1 Polymorphic forms of bortezomib |
| 09/09/2011 | WO2011107911A1 Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid |
| 09/09/2011 | WO2011107903A1 Highly pure mosapride citrate dihydrate and processes for its preparation |
| 09/09/2011 | WO2011107870A2 Compounds and compositions and their use in the treatment of diseases related to copper retention |
| 09/09/2011 | WO2011107866A2 Silyl-derivatives of polysaccharides |
| 09/09/2011 | WO2011107781A1 Biocidal composition and method |
| 09/09/2011 | WO2011107772A1 Molecular targets for healing or treating wounds |
| 09/09/2011 | WO2011107720A1 Paraconic acids as pigmentation activators |
| 09/09/2011 | WO2011107714A1 Cosmetic anti-ageing composition, corresponding use and application method |
| 09/09/2011 | WO2011107710A1 Use of riluzole to treat or prevent the adverse effects of antineoplastic agents |
| 09/09/2011 | WO2011107709A1 Use of isoquinolones for preparing drugs, novel isoquinolones and method for synthesising same |
| 09/09/2011 | WO2011107705A1 Ketobenzofuran derivatives, method for synthesising same, and intermediates |
| 09/09/2011 | WO2011107653A2 Method for treating parkinson's disease |
| 09/09/2011 | WO2011107646A1 Pharmaceutical composition |
| 09/09/2011 | WO2011107630A1 Peritoneal dialysis solution |
| 09/09/2011 | WO2011107617A1 Liquid ibuprofen/codeine pharmaceutical composition for oral administration, the method for preparation thereof and use thereof |
| 09/09/2011 | WO2011107608A1 Heterocyclic amides as rock inhibitors |
| 09/09/2011 | WO2011107585A1 Morpholino substituted urea derivatives as mtor inhibitors |
| 09/09/2011 | WO2011107583A1 Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| 09/09/2011 | WO2011107582A1 Novel pharmaceutical composition for the treatment of neurodegenerative or neurovascular diseases |
| 09/09/2011 | WO2011107498A1 Use of meloxicam for the long-term treatment of kidney disorders in cats |
| 09/09/2011 | WO2011107494A1 Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
| 09/09/2011 | WO2011107474A1 Derivatives of aminoindanes, their preparation and their application in therapeutics |
| 09/09/2011 | WO2011107469A1 Use of ellagic acid as an anti-dandruff agent |
| 09/09/2011 | WO2011107454A1 Process for the preparation of a polymorph of strontium ranelate |
| 09/09/2011 | WO2011107427A1 Dabigatran etexilate-containing oral pharmaceutical composition |
| 09/09/2011 | WO2011107421A1 Products and method |
| 09/09/2011 | WO2011107408A1 Stable pharmaceutical composition comprising bisphosphonate |
| 09/09/2011 | WO2011107394A1 Treatment of anxiety disorders |
| 09/09/2011 | WO2011107334A1 Composition comprising as active ingredient l-carnitine in combination with hydroxykynurennine-0-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation |
| 09/09/2011 | WO2011107295A1 Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
| 09/09/2011 | WO2011107248A1 NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE |
| 09/09/2011 | WO2011107150A1 Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
| 09/09/2011 | WO2011107100A1 Methods and compositions for regulation of herv4 |
| 09/09/2011 | WO2011107023A1 Compounds for preventing and treating disorders of metabolism and uses thereof |
| 09/09/2011 | WO2011107019A1 Antibacterial compounds, preparation methods and uses thereof |
| 09/09/2011 | WO2011107007A1 Polyethylene glycol electrolyte granues and its preparing process |
| 09/09/2011 | WO2011106993A1 Gold nanoparticles modified by aminopyrimide, preparation method and use thereof |
| 09/09/2011 | WO2011106992A1 Inhibitors of hepatitis c virus ns5b polymerase |
| 09/09/2011 | WO2011106986A1 Inhibitors of hepatitis c virus ns5b polymerase |
| 09/09/2011 | WO2011106951A1 Compound pharmaceutical composition of levoamlodipine |
| 09/09/2011 | WO2011106929A1 Inhibitors of hepatitis c virus ns5b polymerase |
| 09/09/2011 | WO2011106924A1 Isoflavone fatty acid ester derivatives, preparation method and pharmaceutical uses thereof |
| 09/09/2011 | WO2011106898A1 Methods and systems for preparing irreversible inhibitors of protein tyrosine phosphatases |
| 09/09/2011 | WO2011106858A1 Fast-dissolving solid pharmaceutical form for treating bacterial infections |
| 09/09/2011 | WO2011106839A1 Skin cancer prevention and treatment |
| 09/09/2011 | WO2011086577A3 Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts |
| 09/09/2011 | WO2011085271A3 Modulation of angiopoietin-like 3 expression |
| 09/09/2011 | WO2011085000A3 Fatty acid derivatives and analogs of drugs |
| 09/09/2011 | WO2011084652A3 Crystalline salts of a factor xa inhibitor |
| 09/09/2011 | WO2011076711A3 Polymorphs of salts of 4- [4- [ [4-chloro-3- (trifluoromethyl) phenyl] carbamoylamino] phenoxy] -n-methylpyridine - 2 - carboxamide |
| 09/09/2011 | WO2011073112A3 Mannose derivatives as antagonists of bacterial adhesion |
| 09/09/2011 | WO2011072012A3 Improved methods and compositions for vein harvest and autografting |
| 09/09/2011 | WO2011066147A3 Crystalline salt forms of a pyrimidin- 5 - yl acetic acid derivative |
| 09/09/2011 | WO2011064559A3 Novel inositol phosphate derivatives |
| 09/09/2011 | WO2011062903A9 Slow infusion of sulcardine and its salts |
| 09/09/2011 | WO2011060253A3 Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms |
| 09/09/2011 | WO2011058027A3 N-9-substituted purine compounds, compositions and methods of use |
| 09/09/2011 | WO2011057241A9 Androstenediol as an indicator for assessing estrogenicity |
| 09/09/2011 | WO2011057204A9 Lrrk2-mediated neuronal toxicity |
| 09/09/2011 | WO2011057145A3 Imidazo[1,2-a] pyridine compounds, synthesis thereof, and methods of using same |
| 09/09/2011 | WO2011057082A9 A method to enhance endurance |
| 09/09/2011 | WO2011056667A3 Rosacea topical skin treatment method and formulation |
| 09/09/2011 | WO2011056630A3 Small molecule inhibitors of hepatitis c virus |
| 09/09/2011 | WO2011051971A3 Solid dispersion of rifaximin |
| 09/09/2011 | WO2011050196A9 Method for treating herpes virus infection |
| 09/09/2011 | WO2011050095A3 Prevention and treatment of post-operative cognitive dysfunction (pocd) |
| 09/09/2011 | WO2011049987A3 Azaindazoles to treat flaviviridae virus infection |
| 09/09/2011 | WO2011049958A3 Modulation of gel temperature of poloxamer-containing formulations |
| 09/09/2011 | WO2011049954A3 Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders |
| 09/09/2011 | WO2011041542A3 Herbal pain killer compositions |
| 09/09/2011 | WO2011037433A3 Use of a quinolone derivative containing 7-(4-aminomethyl-3-oxime)pyrrolidine group that is capable of inducing granulocyte colony stimulating factor for treatment of neutropenia and recovery of hematopoiesis |
| 09/09/2011 | WO2010146409A3 Nanoparticulate candesartan cilexetil compositions, process for the preparation thereof and pharmaceutical compositions containing them |
| 09/09/2011 | WO2010132759A9 Antibacterial derivatives of dibekacin |
| 09/09/2011 | WO2010123960A3 Arylsulfonamide ccr3 antagonists |
| 09/09/2011 | WO2010123956A3 2,5-disubstituted arylsulfonamide ccr3 antagonists |
| 09/09/2011 | WO2010117438A3 Compounds that suppress cancer cells and exhibit antitumor activity |
| 09/09/2011 | WO2010059717A3 Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol |
| 09/09/2011 | CA2829180A1 A novel composition of matter for delivering lipid-soluble materials, and a method for producing it |
| 09/09/2011 | CA2828833A1 Pharmaceutical compositions comprising monoterpenes |